Curosurf

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This product helps improve lung function and oxygenation, often administered via endotracheal tube.

Curosurf is primarily used to manage respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs lack sufficient surfactant, a substance that keeps the air sacs open. By providing exogenous surfactant, Curosurf aids in reducing surface tension within the lungs, facilitating easier breathing and improving oxygen levels. It is typically administered directly into the lungs via an endotracheal tube.

Curosurf works by replacing the natural surfactant in the lungs, which helps to reduce surface tension and improve lung compliance. This can lead to better oxygenation and reduced respiratory effort in premature infants. The effects are generally observed shortly after administration, contributing to improved respiratory function.

Curosurf should be administered by healthcare professionals experienced in neonatal intensive care. It is essential to follow proper handling and storage guidelines to maintain its efficacy. Monitoring the infant's respiratory status and oxygen levels is crucial during and after administration to ensure optimal outcomes.

Curosurf is generally used in a controlled medical setting, and interactions with other medications are not commonly reported. However, it is important to inform healthcare providers about any other treatments the infant is receiving to avoid potential complications. Always consult a healthcare professional for specific advice.